Avidity Biosciences Inc

📅 Upcoming

🕒 Recent(90d)

News

• Trend of women-led M&A fades in 2026 with just two deals so far
  Last year, 11 major M&A deals were signed with women-led biotechs. The industry is nowhere near on track to meet that bar for 2026.
  biospace · 20h ago
• After Novartis’ devastating M&A losses, long live the executive willing to try
  Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular dystrophy and ALS hit major roadblocks this month.
  biospace · 13d ago
• Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
  Novartis stands alongside Big Pharma peers that have similarly invested in technologies to penetrate the blood-brain barrier, including GSK, Roche and Eli Lilly.
  biospace · 13d ago
• Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
  The TREM2 stabilizer failed to show efficacy in a Phase 2 trial of patients with early-stage ALS. This development follows two late-stage trial failures reported by Novartis last week, plus the new…
  biospace · 14d ago
• This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree
  RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmar…
  biopharma_dive · 19d ago
• Frazier adds $1.1B+ to small and mid-sized biotech fund
  Frazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by Merck for $10 billion, and Carmot Therapeutics, which Roche bought for…
  biospace · 19d ago
• Novartis drags peers down with triple asset failure
  Novartis’ shares fell 13% this week after the report of three separate late-stage asset failures. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
  biospace · 19d ago
• Novartis drags peers down with triple asset stumble
  Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
  biospace · 19d ago
• Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
  Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
  biospace · 19d ago
• Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
  Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.
  fiercebiotech · 20d ago